Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 589

Results For "RI"

10423 News Found

GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
News | August 02, 2024

GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.


Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr
News | August 02, 2024

Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr

Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore


Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr
News | August 02, 2024

Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr

Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore


Shilpa Pharma Lifesciences received CEP from EDQM for ursodeoxycholic acid
Drug Approval | August 01, 2024

Shilpa Pharma Lifesciences received CEP from EDQM for ursodeoxycholic acid

Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones


Dr. Jitendra Singh conferred Lifetime Achievement Award
News | August 01, 2024

Dr. Jitendra Singh conferred Lifetime Achievement Award

Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization


Dr. Agarwals Eye Hospital posts standalone Q1 FY25 PAT higher at Rs. 14.11 Cr
News | August 01, 2024

Dr. Agarwals Eye Hospital posts standalone Q1 FY25 PAT higher at Rs. 14.11 Cr

Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024


Ajanta Pharma posts Q1 FY25 consolidated PAT at Rs. 245.77 Cr
News | August 01, 2024

Ajanta Pharma posts Q1 FY25 consolidated PAT at Rs. 245.77 Cr

Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024


Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause
Drug Approval | August 01, 2024

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo


DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control
Policy | August 01, 2024

DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control

More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options


Fredun Pharmaceuticals Q1 FY25 PAT drops QoQ to Rs. 4.12 Cr
News | July 31, 2024

Fredun Pharmaceuticals Q1 FY25 PAT drops QoQ to Rs. 4.12 Cr

Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024